Companies Dominating the Beta Thalassemia Treatment Market
- Bluebird Bio Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Acceleron Pharma, Inc.
- Celgene Corporation
- GlaxoSmithKline plc
- Incyte Corporation
- Gamida Cell
- Kiadis Pharma
- La Jolla Pharmaceutical Company
- Vertix Pharmaceuticals Incorporated
- ApoPharma Inc.
Browse Key Market Insights with Data Illustration:
In the News
- Zynteglo, a new generation of gene therapy for adult and paediatric patients with beta thalassemia that requires regular red cell transfusions, has been authorised by the US Food and Drug Administration.
- CRISPR and Vertex Pharmaceuticals Incorporated announced the Fast Track Designation for CTX001 to treat transfusiondependent beta thalassemia has been given by the United States Food and Drug Administration. CTX001 is an investigational autologous, gene edited therapy of hematopoietic stem cells for patients with severe hemoglobinopathies.
